25 Mg Tablet, Isosorbide Dinitrate 5 Mg Tablet, Rosuvastatin
5 Mg Tablet, etc.
com/research/ccwrrv/investigation) has announced the addition of the "Investigation Report on China's Rosuvastatin
Market, 2010-2019" report to their offering.
HIV-positive people taking rosuvastatin
for 48 weeks had significantly greater gains in bone mineral density than people taking placebo, according to results of a 150-person trial.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12-4, with 1 abstention, that data support the use of rosuvastatin
for the primary prevention of major cardiovascular adverse events in men aged 50 years and older and in women aged 60 years and older with a fasting LDL cholesterol level below 130 mg/dL, high-sensitivity C-reactive protein (hsCRP) level of 2.
In this new analysis of 6,801 women from the JUPITER study, rosuvastatin
20 mg reduced CV events by 46% in women without CVD but at increased risk of a cardiovascular event, as identified by age and elevated hsCRP (p=0.
NYSE: ACT), a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin
calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor[sup.
These patents a formulation patent (AU 200051842, with an expiry date in 2020); a second related to the use of rosuvastatin
for treating heterozygous familial hypercholesterolemia (AU 2002214165, with an expiry date in 2021); and a third related to the use of rosuvastatin
for treating hypercholesterolemia (AU 2000023051, with an expiry date in 2020) were challenged by Apotex Pty Ltd, Watson Pharma Pty Ltd and Ascent Pharma Pty Ltd.
GISSI-Heart Failure (GISSI-HF) was a double-blind, placebo-controlled trial that randomized 4,574 patients with New York Heart Association (NYHA) class II-IV heart failure to fish oil capsules and/or rosuvastatin
at 10 mg/day.
These new data were presented today at the 57th Annual Scientific Session of the American College of Cardiology and showed that rosuvastatin
treatment for 24 months to LDL-C levels well below 70 mg/dL, together with significant increases in HDL-C, produced regression by decreasing percent diameter stenosis and improving minimum lumen diameter as measured by QCA in coronary disease patients.
Earlier this year, initial results from ASTEROID (A Study To Evaluate the Effect of Rosuvastatin
On Intravascular Ultrasound-Derived Coronary Atheroma Burden) suggested that substantial reductions in LDL-C and increases in HDL- C using CRESTOR are associated with the regression of coronary atherosclerosis.
BARCELONA -- Rosuvastatin
for primary prevention of cardiovascular events in elderly patients achieves a relative risk reduction comparable to that seen in younger patients, but with a substantially greater absolute benefit and no increase in treatment-related side effects, according to a new secondary analysis of JUPITER.
i) ASTEROID (A Study To Evaluate the Effect of Rosuvastatin
On Intravascular Ultrasound-Derived Coronary Atheroma Burden) was a 104-week, open label, single-arm, blinded endpoint study designed to study the effect of CRESTOR 40 mg in 507 patients who had undergone coronary angiography and who had evidence of coronary artery disease (CAD).